Philippines

The Food and Drug Administration of the Philippines (FDA Philippines), operating under the Department of Health (DOH), is the primary regulatory authority governing health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions. Its mandate is established under Republic Act No. 9711, known as the Food and Drug Administration Act of 2009, which expanded the agency's authority and strengthened enforcement powers. All health products must obtain a Certificate of Product Registration (CPR) or, for certain devices and diagnostics, a License to Operate (LTO) before they can be legally marketed in the country. The approval process involves product classification, dossier submission, technical evaluation, laboratory testing where required, and issuance of the CPR, with timelines varying significantly depending on product category, risk classification, and application pathway.

For pharmaceutical products, submissions generally follow the ASEAN Common Technical Dossier (ACTD) format, though the ICH Common Technical Document (CTD) is also accepted for products with prior approvals from recognized reference agencies such as the US FDA, EMA, Health Canada, TGA Australia, and PMDA Japan. Medical devices are classified according to a four-tier risk framework (Class A to Class D), with higher-risk classes requiring more extensive documentary evidence. A local authorized representative, typically a duly licensed company holding a valid LTO, is mandatory for foreign manufacturers without a direct Philippine presence. FDA Philippines has pursued regulatory modernization through its Regulatory Reform Agenda, introducing electronic submissions via the FDA eServices portal, expanding the Compassionate Special Permit (CSP) pathway for unregistered products, and implementing ASEAN harmonization commitments. Recent reforms also include the adoption of abbreviated and fast-track review pathways for products already approved by recognized reference agencies, significantly reducing review timelines for eligible applications.

Public procurement of health products in the Philippines is primarily governed by Republic Act No. 9184, the Government Procurement Reform Act, and is administered through multiple channels depending on the nature and end-user of the product. The Department of Health (DOH) serves as the central health authority and procures essential medicines, vaccines, medical devices, and diagnostics for national programs through the Procurement Service of the Department of Budget and Management (PS-DBM) or through agency-level procurement committees. The Philippine Health Insurance Corporation (PhilHealth) plays a critical indirect role by setting benefit packages that determine reimbursable products, effectively shaping demand across public hospitals. Local Government Units (LGUs), which operate provincial and municipal health facilities, conduct their own procurement independently, creating a fragmented landscape where suppliers may need to engage both central and local government buyers. Participation in government tenders typically requires product registration, a valid LTO, compliance with the Philippine National Drug Formulary (PNDF) for pharmaceuticals, and conformance with DOH procurement guidelines including price ceilings under the Generics Act of 1988 and related pricing regulations.

The private sector represents a substantial and growing share of healthcare spending in the Philippines, encompassing private hospitals, pharmacy chains such as Mercury Drug, Watsons, and Rose Pharmacy, and health maintenance organizations (HMOs). Distribution into the private market requires engagement with established local distributors and compliance with FDA registration requirements. Donor-funded procurement channels are also relevant, particularly for infectious disease programs: the Global Fund supports HIV, tuberculosis, and malaria interventions; UNICEF and WHO provide technical and procurement assistance for vaccines and maternal and child health commodities; and USAID through its various implementing partners funds health system strengthening and commodity supply activities. The government has pursued local manufacturing preference policies encouraging domestic production of essential medicines and medical supplies, reinforced during and after the COVID-19 pandemic, with executive issuances promoting local sourcing and the development of a Philippine pharmaceutical manufacturing sector aligned with international Good Manufacturing Practice (GMP) standards.